SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
1 . An article of manufacture containing a single fixed dose of a HER2 antibody comprising the variable light chain and variable heavy chain amino acid sequences of SEQ ID Nos. 7 and 8, respectively, wherein the fixed dose is about 600 mg or about 1200 mg.
2 . The article of manufacture of claim 1 , which is a single-use vial or a syringe.
3 . The article of manufacture of claim 1 , wherein the HER2 antibody is pertuzumab.
4 . The article of manufacture of claim 1 , comprising two single dose vials, wherein a first vial contains a single fixed dose of about 1200 mg of pertuzumab, and a second vial contains a single fixed dose of about 600 mg of pertuzumab.
5 . The article of manufacture of claim 1 , further containing a single fixed dose of trastuzumab.
6 . The article of manufacture of claim 5 , wherein the single fixed dose of pertuzumab and the single fixed dose of trastuzumab are contained in a single liquid formulation for subcutaneous administration.
7 . The article of manufacture of claim 6 , wherein the liquid formulation comprises a single fixed dose of about 600 mg of pertuzumab and a single fixed dose of about 600 mg of trastuzumab.
8 . The article of manufacture of claim 6 , wherein the liquid formulation comprises a single fixed dose of about 1200 mg of pertuzumab and a single fixed dose of about 600 mg of trastuzumab.
9 . The article of manufacture of claim 6 , wherein the liquid formulation further comprises a hyaluronidase enzyme.
10 . The article of manufacture of claim 9 , wherein the hyaluronidase enzyme is recombinant human hyaluronidase PH20 enzyme (rHuPH20).
11 . The article of manufacture of claim 10 , wherein the rHuPH20 is present in the liquid formulation in an amount sufficient to result in an increase in the dispersion of the pertuzumab and trastuzumab contained in the same liquid formulation during subcutaneous administration.
12 . The article of manufacture of claim 11 , wherein the rHuPH20 is present in the liquid formulation at a concentration of at least about 600 U/mL.
13 . The article of manufacture of claim 12 , wherein the rHuPH20 is present in the liquid formulation at a concentration of about 1,000 U/mL or about 2,000 U/mL.
14 . The article of manufacture of claim 5 , further comprising a package insert instructing the user to administer the fixed doses of pertuzumab and trastuzumab subcutaneously to a patient with HER2 positive cancer.
15 . The article of manufacture of claim 14 , wherein the package insert instructs the user to co-administer the fixed dose pertuzumab and the fixed dose of trastuzumab subcutaneously as two separate subcutaneous injections.
16 . The article of manufacture of claim 14 , wherein the package insert instructs the user to administer the fixed dose pertuzumab co-mixed with the fixed-dose trastuzumab as a single subcutaneous injection.
17 . The article of manufacture of any one of claim 14 , wherein the package insert instructs the user to administer a fixed dose combination of pertuzumab and trastuzumab as a single subcutaneous injection.
18 . The article of manufacture of claim 14 , wherein the HER2 positive cancer is selected from the group consisting of breast cancer, peritoneal cancer, fallopian tube cancer, lung cancer, colorectal cancer, biliary cancer and bladder cancer.
19 . The article of manufacture of claim 14 , wherein the HER2 positive cancer is early breast cancer (EBC) or metastatic breast cancer (MBC).
20 . An aqueous formulation for subcutaneous administration comprising pertuzumab at a concentration of about 120 mg/mL, recombinant human hyaluronidase PH20 enzyme (rHuPH20) at a concentration of about 1000 to 2000 U/mL, a histidine buffer to adjust to pH to about 5.5 to 5.7, sucrose, methionine, and polysorbate 20.
21 . The aqueous formulation of claim 20 , wherein the rHuPH20 is present at a concentration of about 1000 U/mL or 2000 U/mL.
22 . A liquid subcutaneous pharmaceutical composition comprising a fixed dose of pertuzumab and a fixed dose of trastuzumab co-formulated in an aqueous solution further comprising recombinant human hyaluronidase PH20 enzyme (rHuPH20), a buffering agent suitable to adjust the pH to about 5.0 to 6.0, a stabilizer, and a surfactant.
23 . The liquid subcutaneous pharmaceutical composition of claim 22 , wherein the buffering agent is a histidine buffer.
24 . The liquid subcutaneous pharmaceutical composition of claim 23 , wherein the buffering agent is histidine acetate.
25 . The liquid subcutaneous pharmaceutical composition of claim 22 , wherein the pH is about 5.5 to 5.7.
26 . The liquid pharmaceutical composition of claim 22 , comprising sucrose as a stabilizer, methionine as a stabilizer, trehalose as a stabilizer, and polysorbate 20 as a surfactant.
27 . A liquid pharmaceutical composition comprising 600 mg pertuzumab at a concentration of 60 mg/mL, 600 mg trastuzumab at a concentration of 60 mg/mL, 1,000 U/mL or 2,000 U/mL recombinant human hyaluronidase PH20 enzyme (rHuPH20), 20 mM Histidine-HCl pH 5.5, 105 mM trehalose, 100 mM sucrose, 0.04% polysorbate 20, 10 mM methionine, and sterile water for injection up to a total volume of 10 mL.
28 . The liquid pharmaceutical composition of claim 27 , contained in a 15 mL vial.
29 . A liquid pharmaceutical composition comprising 1200 mg pertuzumab at a concentration of 80 mg/mL, 600 mg trastuzumab at a concentration of 40 mg/mL, 1,000 U/mL or 2,000 U/mL recombinant human hyaluronidase PH20 enzyme (rHuPH20), 20 mM Histidine-HCl pH 5.5, 70 mM trehalose, 133 mM sucrose, 0.04% polysorbate 20, 10 mM methionine, and sterile water for injection up to a total volume of 15 mL.
30 . The liquid pharmaceutical composition of claim 29 , contained in a 20 mL vial.